QIAGEN Inc. Reports Results For First Quarter 2015
VENLO, The Netherlands, May 5, 2015 /PRNewswire/ --
•Q1 2015 results: Adjusted net sales of $298.7 million (+2% CER); adjusted operating income of $67.4 million; and adjusted EPS of $0.22 ($0.24 CER)
•Adjusted net sales rise 8% CER excluding reduced HPV sales in U.S.
•Investments transforming QIAGEN and strengthening expansion
•Free cash flow rises 40% to $39.7 million
•QIAGEN reaffirms expectations for higher 2015 CER adjusted net sales and earnings; expect adverse impact on reported results from currency movements
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter of 2015, delivering on goals for higher adjusted net sales and earnings at constant exchange rates (CER).
"Our results for the first quarter of 2015 show QIAGEN continues to deliver a solid performance while moving ahead on our transformation and preparations for a new growth wave. We are building momentum through our portfolio of growth drivers, which represent about 30% of sales and are expanding at a double-digit pace as we invest in new products and key markets. During the first quarter, QIAGEN further advanced its leadership in the rapidly emerging market for liquid biopsies, using non-invasive blood tests to obtain valuable molecular insights. The launches of the fourth-generation QuantiFERON-TB Gold Plus test to support the fight on tuberculosis and the QuantiFERON Monitor test to address a large unmet need for monitoring immune function in transplant patients are building momentum. Sales of HPV test products in the U.S. continue to decline due to pricing pressure, but it now represents only 4% of total sales, and we expect 2015 to be the final year of significant challenges. We are reaffirming our goals for higher adjusted sales and earnings at constant exchange rates in 2015 as we move forward on our strategic ambitions to offer Sample to Insight solutions to our customers," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
•Q1 2015 results: Adjusted net sales of $298.7 million (+2% CER); adjusted operating income of $67.4 million; and adjusted EPS of $0.22 ($0.24 CER)
•Adjusted net sales rise 8% CER excluding reduced HPV sales in U.S.
•Investments transforming QIAGEN and strengthening expansion
•Free cash flow rises 40% to $39.7 million
•QIAGEN reaffirms expectations for higher 2015 CER adjusted net sales and earnings; expect adverse impact on reported results from currency movements
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter of 2015, delivering on goals for higher adjusted net sales and earnings at constant exchange rates (CER).
"Our results for the first quarter of 2015 show QIAGEN continues to deliver a solid performance while moving ahead on our transformation and preparations for a new growth wave. We are building momentum through our portfolio of growth drivers, which represent about 30% of sales and are expanding at a double-digit pace as we invest in new products and key markets. During the first quarter, QIAGEN further advanced its leadership in the rapidly emerging market for liquid biopsies, using non-invasive blood tests to obtain valuable molecular insights. The launches of the fourth-generation QuantiFERON-TB Gold Plus test to support the fight on tuberculosis and the QuantiFERON Monitor test to address a large unmet need for monitoring immune function in transplant patients are building momentum. Sales of HPV test products in the U.S. continue to decline due to pricing pressure, but it now represents only 4% of total sales, and we expect 2015 to be the final year of significant challenges. We are reaffirming our goals for higher adjusted sales and earnings at constant exchange rates in 2015 as we move forward on our strategic ambitions to offer Sample to Insight solutions to our customers," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.